Literature DB >> 2861621

A comparison between chlordiazepoxide and CL 218,872--a synthetic nonbenzodiazepine ligand for benzodiazepine receptors on spontaneous locomotor activity in rats.

J F McElroy, R L Fleming, R S Feldman.   

Abstract

Spontaneous locomotor activity was investigated in rats treated with chlordiazepoxide (CDP) or CL 218,872, a synthetic nonbenzodiazepine ligand for benzodiazepine receptors. Acute administration of CDP (2.5 mg/kg) increased activity, whereas a higher dose (10 mg/kg) decreased activity. Acute injection of CL 218,872 (2.5-10 mg/kg) produced a significant dose-dependent suppression of locomotor activity, a finding at variance with a previous report that anxiolytic doses of CL 218,872 are devoid of depressant side effects. Chronic pretreatment with CDP or CL 218,872 (10 mg/kg daily for 6 days) produced a tolerance to the sedative effect of CDP (10 mg/kg), but not to the activity suppressant action of CL 218,872 (10 mg/kg).

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2861621     DOI: 10.1007/bf00428419

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  14 in total

Review 1.  Behavioral analysis of the effects and mechanisms of action of benzodiazepines.

Authors:  L Cook; J Sepinwall
Journal:  Adv Biochem Psychopharmacol       Date:  1975

2.  Increase of "antianxiety" activity and tolerance of behavioral depression during chronic administration of oxazepam.

Authors:  D L Margules; L Stein
Journal:  Psychopharmacologia       Date:  1968

3.  Metabolism and tolerance studies with chlordiazepoxide-2-l4C in the rat.

Authors:  D R Hoogland; T S Miya; W F Bousquet
Journal:  Toxicol Appl Pharmacol       Date:  1966-07       Impact factor: 4.219

Review 4.  Benzodiazepines and ethanol: assessment of the effects and consequences of psychotropic drug interactions.

Authors:  E M Sellers; U Busto
Journal:  J Clin Psychopharmacol       Date:  1982-08       Impact factor: 3.153

5.  Generalization between benzodiazepine- and triazolopyridazine-elicited discriminative cues.

Authors:  J F McElroy; R S Feldman
Journal:  Pharmacol Biochem Behav       Date:  1982-10       Impact factor: 3.533

6.  Differences among 'serotonergic' anorectics in a cross-tolerance paradigm: do they all act on serotonin systems?

Authors:  N Rowland; S M Antelman; D Kocan
Journal:  Eur J Pharmacol       Date:  1982-06-16       Impact factor: 4.432

7.  Anti-conflict and depressant effects by GABA agonists and antagonists, benzodiazepines and non-gabergic anticonvulsants on self-stimulation and locomotor activity.

Authors:  L J Herberg; S F Williams
Journal:  Pharmacol Biochem Behav       Date:  1983-10       Impact factor: 3.533

8.  A synthetic non-benzodiazepine ligand for benzodiazepine receptors: a probe for investigating neuronal substrates of anxiety.

Authors:  A S Lippa; J Coupet; E N Greenblatt; C A Klepner; B Beer
Journal:  Pharmacol Biochem Behav       Date:  1979-07       Impact factor: 3.533

9.  Neurons in the frontal cortex of the rat carry multiple opiate receptors.

Authors:  J T Williams; W Zieglgänsberger
Journal:  Brain Res       Date:  1981-12-07       Impact factor: 3.252

10.  Morphine- and methadone-tolerant mice differ in cross-tolerance to other opiates. Heterogeneity in opioid mechanisms indicated.

Authors:  A Neil
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-07       Impact factor: 3.000

View more
  11 in total

1.  Effects of ritanserin and chlordiazepoxide on sleep-wakefulness alterations in rats following chronic cocaine treatment.

Authors:  C Dugovic; T F Meert; D Ashton; G H Clincke
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

2.  Effects of non-sedative anxiolytic drugs on responses to GABA and on diazepam-induced enhancement of these responses on mouse neurones in cell culture.

Authors:  P P De Deyn; R L Macdonald
Journal:  Br J Pharmacol       Date:  1988-09       Impact factor: 8.739

3.  Sleep and benzodiazepine receptor sub-types.

Authors:  W B Mendelson; J V Martin; M Perlis; R Wagner
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

4.  In vivo benzodiazepine receptor occupancy by CL 218,872 visualized by positron emission tomography in the brain of the living baboon: modulation by GABAergic transmission and relation with anticonvulsant activity.

Authors:  V de la Sayette; C Chavoix; E Brouillet; P Hantraye; M Kunimoto; M Khalili-Varasteh; B Guibert; C Prenant; M Mazière
Journal:  Exp Brain Res       Date:  1991       Impact factor: 1.972

5.  Tolerance, cross-tolerance and dependence measured by operant responding in rats treated with triazolam via osmotic pumps.

Authors:  C Cohen; D J Sanger
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

6.  Lateral habenular norepinephrine contributes to states of arousal and anxiety in male rats.

Authors:  Erin M Purvis; Adam K Klein; Aaron Ettenberg
Journal:  Behav Brain Res       Date:  2018-03-09       Impact factor: 3.332

7.  A 7-phenyl substituted triazolopyridazine has inverse agonist activity at the benzodiazepine receptor site.

Authors:  K Biziere; J J Bourguignon; J P Chambon; M Heaulme; A Perio; S Tebib; C G Wermuth
Journal:  Br J Pharmacol       Date:  1987-01       Impact factor: 8.739

8.  A comparison between chlordiazepoxide and CL 218,872, a synthetic non-benzodiazepine ligand for benzodiazepine receptors, on serotonin and catecholamine turnover in brain.

Authors:  J F McElroy; R S Feldman; J S Meyer
Journal:  Psychopharmacology (Berl)       Date:  1986       Impact factor: 4.530

9.  Like diazepam, CL 218,872, a selective ligand for the benzodiazepine omega 1 receptor subtype, impairs place learning in the Morris water maze.

Authors:  R K McNamara; R W Skelton
Journal:  Psychopharmacology (Berl)       Date:  1992       Impact factor: 4.530

10.  Comparison of the effects of chlordiazepoxide and CL 218,872 on serum corticosterone concentrations in rats.

Authors:  J F McElroy; J M Miller; J S Meyer
Journal:  Psychopharmacology (Berl)       Date:  1987       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.